Product news from the 10/03/06 News Brief

Share this article:
The FDA granted expanded indication to GlaxoSmithKline’s anti-seizure medicine Lamictal (lamotrigine) for treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, also known as "grand mal" seizures, in children aged 2 and older and adults. Axcan Pharma said the FDA has issued an approval letter for the company's New Drug Application for Pylera (formerly Helizide). Pylera is a patented 3-in-1 capsule triple therapy, for the eradication of Helicobacter pylori, a bacterium recognized as being the main cause of gastric and duodenal ulcers. Gilead Sciences has agreed to acquire Myogen in a deal worth approximately $2.5 billion. The deal means that Gilead will acquire Myogen's main drug candidate, Ambrisentan, a pulmonary arterial hypertension treatment in late-stage clinical trials.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.